公开(公告)号：US20240082240A1

公开(公告)日：2024-03-14

申请号：US18385686

申请日：2023-10-31

Applicant: NOVMETAPHARMA CO, LTD.

Inventor： In-Kyu LEE ,  Jae-Han JEON ,  Dipanjan CHANDA ,  Eun Jung CHOI ,  Hoe Yune JUNG ,  Heon Jong LEE

IPC: A61K31/495

CPC classification number: A61K31/495

Abstract: A composition for preventing and/or treating cytokine release syndrome and a method of prevention and/or treatment of cytokine release syndrome are disclosed. The composition includes an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof. The cytokine release syndrome may be caused by virulent infection. The administration of the compound reduces the pre-inflammatory cytokine levels in the subject.

公开(公告)号：US11850246B2

公开(公告)日：2023-12-26

申请号：US17393587

申请日：2021-08-04

Applicant: NOVMETAPHARMA CO., LTD.

Inventor： In-Kyu Lee ,  Jae-Han Jeon ,  Dipanjan Chanda ,  Eun Jung Choi ,  Hoe-Yune Jung ,  Heon Jong Lee

IPC: A61K31/495 ,  A61P29/00

CPC classification number: A61K31/495

Abstract: A composition for preventing and/or treating cytokine release syndrome and a method of prevention and/or treatment of cytokine release syndrome are disclosed. The composition includes an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof. The cytokine release syndrome may be caused by virulent infection. The administration of the compound reduces the pre-inflammatory cytokine levels in the subject.

公开(公告)号：US11820834B2

公开(公告)日：2023-11-21

申请号：US16901676

申请日：2020-06-15

Applicant: NovMetaPharma Co., Ltd.

Inventor： Kay Olmstead ,  David Pearson ,  Elaine McPherson

IPC: C07D487/04 ,  C07K5/12 ,  A61K9/19 ,  A61K47/02

CPC classification number: C07K5/12 ,  A61K9/19 ,  A61K47/02

Abstract: The present disclosure relates to synthesis and characterization of novel polymorphic forms of Cyclo (-His-Pro) (“CHP”).

公开(公告)号：US20230017330A1

公开(公告)日：2023-01-19

申请号：US17779826

申请日：2020-11-26

Applicant: NOVMETAPHARMA CO., LTD.

Inventor： Keun Gyu PARK ,  In Kyu LEE ,  Sung Jin CHO ,  Yeon Kyung CHOI ,  Mi Jin KIM ,  Jung Wook CHIN ,  Yong Hyun JEON ,  Jin A KIM ,  Dong Su KIM ,  Hoe Yune JUNG

IPC: A61K31/495 ,  C07K16/28 ,  C12N15/115 ,  A61K31/7105 ,  A61K31/44 ,  A61P35/00 ,  G01N33/574 ,  G01N33/68

Abstract: The present invention relates to a pharmaceutical composition for inhibiting the resistance of liver cancer to sorafenib and enhancing an anticancer effect, comprising an Estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. The present invention can be effectively used as a pharmaceutical composition for treating sorafenib-resistant advanced liver cancer.

公开(公告)号：US20250011267A1

公开(公告)日：2025-01-09

申请号：US18712003

申请日：2022-11-22

Applicant: NovMetaPharma Co., Ltd.

Inventor： Hoe Yune JUNG ,  Heonjong LEE

IPC: C07C39/23

Abstract: Provided is a process for preparing an aryl ethene compound of formula (1) having high purity with high yield via a simple process. Also, disclosed is a process for preparing a dihydrochloride salt of the compound of formula (1), containing the step of reacting the compound of formula (1) with hydrogen chloride.

公开(公告)号：US20240261366A1

公开(公告)日：2024-08-08

申请号：US18427249

申请日：2024-01-30

Applicant: NOVMETAPHARMA CO., LTD. ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hail KIM ,  Hoeyune JUNG ,  Kyun Hoo KIM ,  Joonyub LEE ,  Hyeonkyu LEE ,  Heon Jong LEE

IPC: A61K38/12 ,  A61K33/30 ,  A61K45/06 ,  A61P1/18

CPC classification number: A61K38/12 ,  A61K33/30 ,  A61K45/06 ,  A61P1/18

Abstract: A method and composition for treating and/or preventing β-cell dysfunction and/or protecting impaired β-cells are disclosed. The method includes administering an effective amount of cyclo (his-pro) (CHP), alone or with zinc, to a subject. The composition contains an effective amount of cyclo (his-pro) (CHP) as an active ingredient. The composition may further contain zinc and/or other antidiabetic agent, or can be administered in combination with zinc and/or other antidiabetic agent.

公开(公告)号：US20240197816A1

公开(公告)日：2024-06-20

申请号：US18533699

申请日：2023-12-08

Applicant: NovMetaPharma Co., Ltd. ,  Seoul National University R&DB Foundation ,  SEOUL NATIONAL UNIVERSITY HOSPITAL

Inventor： Seung Hee Yang ,  Hoeyune Jung ,  Jong Min Kim ,  Yon Su Kim ,  Heonjong Lee

IPC: A61K38/12 ,  A61K45/06 ,  A61P37/06

CPC classification number: A61K38/12 ,  A61K45/06 ,  A61P37/06

Abstract: A treatment of rejection of a transplant by a recipient of the transplant is disclosed. Methods for prolonging transplant survival in a recipient of the transplant, prolonging survival of the recipient, delaying and/or suppressing delayed graft function in the recipient, and/or reducing the amount of an immunosuppressant administered for transplantation. The methods include providing the transplant with a CHP or a pharmaceutically acceptable salt thereof is disclosed. Also provided is a method for the production of a pharmaceutical composition for the treatment of a transplant allowing modulating transplant survival in a recipient of the transplant.

公开(公告)号：US11547737B2

公开(公告)日：2023-01-10

申请号：US17350170

申请日：2021-06-17

Applicant: NovMetaPharma Co., Ltd.

Inventor： Hoe-Yune Jung ,  Heonjong Lee ,  Dohyun Lee

IPC: A61K38/05 ,  A61K31/685 ,  A61K31/56 ,  A61K31/315

Abstract: Compositions and methods for treating viral infection are disclosed. The compositions contain a combination of zinc and a cyclo(His-Pro), in effective amounts. The composition containing a combination of zinc and a cyclo(His-Pro) can be used to treat viral infections including SARS-CoV-2 infections in mammals.

公开(公告)号：US20220202897A1

公开(公告)日：2022-06-30

申请号：US17599211

申请日：2020-03-30

Applicant: NOVMETAPHARMA CO., LTD. ,  SEOUL NATIONAL UNIVERSITY HOSPITAL ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Hoe Yune JUNG ,  Heon Jong LEE ,  Jong Su JEON ,  Do Hyun LEE ,  Yon Su KIM ,  Seung Hee YANG ,  Yong Chul KIM ,  Jong Joo MOON ,  Ji Eun KIM

IPC: A61K38/12 ,  A61P19/04 ,  A61P11/00 ,  A61P1/16

Abstract: A Cyclo (his-pro) (CHP) is useful for preventing, ameliorating, or treating fibrosis. A pharmaceutical composition containing CHP may be used for preventing or treating fibrosis. A health functional food composition containing CHP may be used for preventing or ameliorating fibrosis. An antifibrotic composition, a method of preventing, ameliorating, or treating fibrosis by using CHP, and/or a use of CHP in the manufacture of the pharmaceutical composition for preventing or treating fibrosis are disclosed.

公开(公告)号：US20220193179A1

公开(公告)日：2022-06-23

申请号：US17599118

申请日：2020-03-30

Applicant: NOVMETAPHARMA CO., LTD. ,  SEOUL NATIONAL UNIVERSITY HOSPITAL ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Hoe Yune JUNG ,  Do Hyun LEE ,  Heon Jong LEE ,  Yon Su KIM ,  Seung Hee YANG

IPC: A61K38/01 ,  A61P43/00 ,  A23L33/18

Abstract: A cyclo(His-Pro)(CHP) is useful for preventing, alleviating or treating peritoneal fibrosis. A pharmaceutical composition for preventing or treating peritoneal fibrosis, a dietary supplement composition for preventing or alleviating peritoneal fibrosis, and a peritoneal dialysis solution, which all contain CHP is disclosed. Also disclosed are a method for preventing or treating peritoneal fibrosis by using CHP, a peritoneal dialysis method using CHP, a use of CHP during the preparation of a pharmaceutical composition for preventing or treating peritoneal fibrosis, and/or a use of CHP in the preparation of a peritoneal dialysis solution.